KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Other Working Capital Changes: 2016-2024

Historic Other Working Capital Changes for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to -$439.0 million.

  • Moderna's Other Working Capital Changes rose 87.00% to -$42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.0 million, marking a year-over-year increase of 85.53%. This contributed to the annual value of -$439.0 million for FY2024, which is 78.69% up from last year.
  • Moderna's Other Working Capital Changes amounted to -$439.0 million in FY2024, which was up 78.69% from -$2.1 billion recorded in FY2023.
  • In the past 5 years, Moderna's Other Working Capital Changes ranged from a high of $3.8 billion in FY2020 and a low of -$4.2 billion during FY2022.
  • Moreover, its 3-year median value for Other Working Capital Changes was -$2.1 billion (2023), whereas its average is -$2.2 billion.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first skyrocketed by 8,831.82% in 2020, then tumbled by 247.20% in 2022.
  • Over the past 5 years, Moderna's Other Working Capital Changes (Yearly) stood at $3.8 billion in 2020, then declined by 26.50% to $2.8 billion in 2021, then tumbled by 247.20% to -$4.2 billion in 2022, then skyrocketed by 50.45% to -$2.1 billion in 2023, then skyrocketed by 78.69% to -$439.0 million in 2024.